Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 07 2022 - 4:01PM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with cancer and
autoimmune diseases, today reported the grant of an aggregate of
31,730 restricted stock units of Atara’s common stock to 10 newly
hired employees and stock options to purchase an aggregate of
30,819 shares of Atara’s common stock to four such newly hired
employees. These awards were approved by the Compensation Committee
of Atara’s Board of Directors and granted under the Atara
Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of
February 1, 2022, as an inducement material to the new employees
entering into employment with Atara, in accordance with Nasdaq
Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent
vesting on the first quarterly vesting date after the first
anniversary of the vesting commencement date and the remainder
vesting in 12 approximately equal quarterly installments over the
following three years, subject to the employee being continuously
employed by Atara as of such vesting dates. The stock options vest
over four years, with 25 percent vesting on the first anniversary
of the vesting commencement date for such employee and the
remainder vesting in 36 equal monthly installments over the
following three years, subject to the employee being continuously
employed by Atara as of such vesting dates. The stock options have
a ten-year term and an exercise price of $15.47 per share, equal to
the per share closing price of Atara’s common stock as reported by
Nasdaq on February 1, 2022.
Atara is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell
immunotherapy leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with serious
diseases including solid tumors, hematologic cancers and autoimmune
disease. With our lead program in Phase 3 clinical development and
currently under review to support registration in Europe, Atara is
the most advanced allogeneic T-cell immunotherapy company and
intends to rapidly deliver off-the-shelf treatments to patients
with high unmet medical need. Our platform leverages the unique
biology of EBV T cells and has the capability to treat a wide range
of EBV-associated diseases, or other serious diseases through
incorporation of engineered CARs (chimeric antigen receptors) or
TCRs (T-cell receptors). Atara is applying this one platform, which
does not require TCR or HLA gene editing, to create a robust
pipeline including: tab-cel® (tabelecleucel) in Phase 3 development
for Epstein-Barr virus-driven post-transplant lymphoproliferative
disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV
antigens as a potential treatment for multiple sclerosis; and
multiple next-generation chimeric antigen receptor T-cell (CAR-T)
immunotherapies for both solid tumors and hematologic malignancies.
Improving patients’ lives is our mission and we will never stop
working to bring transformative therapies to those in need. Atara
is headquartered in South San Francisco and our leading-edge
research, development and manufacturing facility is based in
Thousand Oaks, California. For additional information about the
company, please visit atarabio.com and follow us on Twitter and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220207005829/en/
INVESTOR & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com
Media Alex Chapman 805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Oct 2023 to Oct 2024